Zobrazeno 1 - 10
of 249
pro vyhledávání: '"Borrebaeck CA"'
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 269 (2012)
Abstract Background The transcription factor SOX11 is of diagnostic and prognostic importance in mantle cell lymphoma (MCL) and epithelial ovarian cancer (EOC), respectively. Thus, there is an unmet clinical and experimental need for SOX11-targeting
Externí odkaz:
https://doaj.org/article/9abc90e4116c492e80ed299e29f96b34
Autor:
Rexhepaj Elton, Gallagher William M, Brennan Donal J, Gustavsson Elin, Sernbo Sandra, Rydnert Frida, Jirström Karin, Borrebaeck Carl AK, Ek Sara
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 405 (2011)
Abstract Background The neural transcription factor SOX11 has been described as a prognostic marker in epithelial ovarian cancers (EOC), however its role in individual histological subtypes and tumour grade requires further clarification. Furthermore
Externí odkaz:
https://doaj.org/article/80020e6e060d4f09acc2ec92e5e4720d
Publikováno v:
BMC Genomics, Vol 12, Iss 1, p 399 (2011)
Abstract Background Allergic contact dermatitis is an inflammatory skin disease that affects a significant proportion of the population. This disease is caused by an adverse immune response towards chemical haptens, and leads to a substantial economi
Externí odkaz:
https://doaj.org/article/2a858ac85f004a9aafb9c811d4a7119f
Autor:
Brennan Donal J, Andersson Elin, Sernbo Sandra, Gustavsson Elin, Dictor Michael, Jerkeman Mats, Borrebaeck Carl AK, Ek Sara
Publikováno v:
Molecular Cancer, Vol 9, Iss 1, p 187 (2010)
Abstract Background The transcription factor SOX11 plays an important role in embryonic development of the central nervous system (CNS) and is expressed in the adult immature neuron but is normally not expressed in any other adult tissue. It has rece
Externí odkaz:
https://doaj.org/article/c5e84aca86da4b4fbd27b9062eef7732
Autor:
Delfani P; 1 Department of Immunotechnology and CREATE Health, Lund University, Lund, Sweden., Sturfelt G; 2 Department of Clinical Sciences, Rheumatology Section, Lund University Hospital, Lund University, Lund, Sweden., Gullstrand B; 2 Department of Clinical Sciences, Rheumatology Section, Lund University Hospital, Lund University, Lund, Sweden., Carlsson A; 1 Department of Immunotechnology and CREATE Health, Lund University, Lund, Sweden., Kassandra M; 1 Department of Immunotechnology and CREATE Health, Lund University, Lund, Sweden., Borrebaeck CA; 1 Department of Immunotechnology and CREATE Health, Lund University, Lund, Sweden., Bengtsson AA; 2 Department of Clinical Sciences, Rheumatology Section, Lund University Hospital, Lund University, Lund, Sweden., Wingren C; 1 Department of Immunotechnology and CREATE Health, Lund University, Lund, Sweden.
Publikováno v:
Lupus [Lupus] 2017 Apr; Vol. 26 (4), pp. 373-387. Date of Electronic Publication: 2016 Sep 30.
Autor:
Borrebaeck CA; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village (Bldg 406), Lund University, 223 81 Lund, Sweden.
Publikováno v:
Nature reviews. Cancer [Nat Rev Cancer] 2017 Mar; Vol. 17 (3), pp. 199-204. Date of Electronic Publication: 2017 Feb 03.
Autor:
Malmborg A; SenzaGen AB, Medicon Village, S-223 81 Lund, Sweden. amh@senzagen.com., Borrebaeck CA; SenzaGen AB, Medicon Village, S-223 81 Lund, Sweden. carl.borrebaeck@immun.lth.se.; Department of Immunotechnology, Lund University, Medicon Village (bldg 406), S-223 81 Lund, Sweden. carl.borrebaeck@immun.lth.se.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2017 Jan 24; Vol. 18 (2). Date of Electronic Publication: 2017 Jan 24.
Autor:
Pauly F; Department of Immunotechnology, Lund University, Lund, Sweden.; CREATE Health, Lund University, Lund, Sweden., Fjordén K; Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden., Leppä S; Department of Oncology, Helsinki University Hospital, Helsinki, Finland., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Björkholm M; Department of Medicine, Karolinska University Hospital, Stockholm, Sweden., Fluge Ø; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Møller Pedersen L; Department of Hematology, Roskilde Hospital, Roskilde, Denmark., Eriksson M; Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden., Isinger-Ekstrand A; Department of Immunotechnology, Lund University, Lund, Sweden.; CREATE Health, Lund University, Lund, Sweden., Borrebaeck CA; Department of Immunotechnology, Lund University, Lund, Sweden.; CREATE Health, Lund University, Lund, Sweden., Jerkeman M; Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden., Wingren C; Department of Immunotechnology, Lund University, Lund, Sweden.; CREATE Health, Lund University, Lund, Sweden.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2016 Nov 18; Vol. 6 (11), pp. e501. Date of Electronic Publication: 2016 Nov 18.
Autor:
Gerdtsson AS; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: anna.sandstrom@immun.lth.se., Wingren C; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: christer.wingren@immun.lth.se., Persson H; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: helena.persson@immun.lth.se., Delfani P; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: payam.delfani@immun.lth.se., Nordström M; Immunovia AB, Medicon Village, SE 223 81 Lund, Sweden. Electronic address: malin.nordstrom@immunovia.se., Ren H; Tianjin Medical University Cancer Institute & Hospital, Huan-Hu-Xi Road, Ti-Huan-Bei, He Xi District, Tianjin 300060, PR China. Electronic address: renhe@tjmuch.com., Wen X; Tianjin Medical University Cancer Institute & Hospital, Huan-Hu-Xi Road, Ti-Huan-Bei, He Xi District, Tianjin 300060, PR China. Electronic address: xinwen8685@163.com., Ringdahl U; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: ulrika.ringdahl@skane.se., Borrebaeck CA; Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village bldg. 406, Lund University, SE 223 81 Lund, Sweden. Electronic address: carl.borrebaeck@immun.lth.se., Hao J; Tianjin Medical University Cancer Institute & Hospital, Huan-Hu-Xi Road, Ti-Huan-Bei, He Xi District, Tianjin 300060, PR China. Electronic address: haojihui@tjmuch.com.
Publikováno v:
Molecular oncology [Mol Oncol] 2016 Oct; Vol. 10 (8), pp. 1305-16. Date of Electronic Publication: 2016 Jul 12.
Autor:
Säll A; Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden., Persson H; Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden; Science for Life Laboratory, Royal Institute of Technology, Stockholm, Sweden., Ohlin M; Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden., Borrebaeck CA; Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden. Electronic address: Carl.Borrebaeck@immun.lth.se., Wingren C; Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden. Electronic address: Christer.Wingren@immun.lth.se.
Publikováno v:
New biotechnology [N Biotechnol] 2016 Sep 25; Vol. 33 (5 Pt A), pp. 503-13. Date of Electronic Publication: 2015 Dec 15.